Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 4Phase 2/3 2Phase 1/2 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Adenocarcinoma of Lung 2Recurrence 1Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Radiotherapy 8camrelizumab 3Drug Therapy 3Cisplatin 3sintilimab 2Paclitaxel 2Neoadjuvant Therapy 2toripalimab 1tislelizumab 1pembrolizumab 1durvalumab 1anlotinib 1Surgical Procedures, Operative 1Radiofrequency Ablation 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Observation 1Narrow Band Imaging 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Fluorouracil 1Fluorodeoxyglucose F18 1Esophagectomy 1Endoscopy, Digestive System 1Docetaxel 1Consolidation Chemotherapy 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Esophageal Squamous Cell Carcinoma × tislelizumab × Clear all
NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Sichuan University

Phase NA Not yet recruiting
98 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡